前列地尔辅助治疗乙型肝炎肝硬化的效果及对血清炎性因子的影响

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of auxiliary treatment of Alprostadil in the hepatitis B cirrhosis and its influence on serum inflammatory factors.Methods A total of 80 patients with hepatitis B cirrhosis admitted to our hospital from June 2016 to June 2017 were divided into group A (n=40)and group B (n=40)according to systic randomazition method.Group A was treated with Telbivudine on the basis of conventional treatment,group B was given Alprostadil for auxiliary treatment on the basis of group A.The clinical efficacy of the two groups of patients after 3 months of treatment,the hepatitis B virus DNA level and the inflammatory factors levels including interleukin-6(IL-6),interleukin-22(IL-22)and high-sensitivity C reactive protein(hs-CRP)before and after treatment were compared.ResultsThe total effective rate in group B(90.00%)was higher than that in group A(67.50%),with statistically significant difference (P<0.05).The levels of HBV DNA after treatment in both groups were lower than those before treatment,but there was no significant difference between the two groups (P＞0.05).The levels of hs-CRP,IL-6 and IL-22 in two groups after treatment were lower than those before treatment,and the above indexes in group B were lower than those in group A,with statistically significant difference(P<0.05).Conclusion Alprostadil has a good adjuvant therapy for patients with hepatitis B cirrhosis,which can effectively control the DNA level of hepatitis B virus and the levels of inflammatory cytokines such as hs-CRP,IL-6 and IL-22.

Key words： Hepatitis B cirrhosis Alprostadil Telbivudine Clinical efficacy Hepatitis B virus DNA Inflammatory factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Ke-wei
	XIAO Can-hui
	BAI Yu-yan
	PING Qu

Cite this article:

ZHU Ke-wei,XIAO Can-hui,BAI Yu-yan, et al. Effect of auxiliary treatment of Alprostadil in the hepatitis B cirrhosis and its influence on serum inflammatory factors[J]. 中国当代医药, 2018, 25(15): 102-104.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I15/102

[1]	刘玉玲，冯振清，贾秋龙，等.恩替卡韦联合前列地尔对乙型肝炎肝硬化腹水患者肝肾功能恢复及预后的影响[J].慢性病学杂志，2017，18（9）：1038-1040.
[2]	王红喜，孙艳艳.肝硬化患者间断静脉推注前列地尔对静脉影响的观察[J].山东医学高等专科学校学报，2016，38（2）：97-98.
[3]	祁涛.替比夫定治疗失代偿期乙肝肝硬化的疗效及安全性[J].北方药学，2018，15（1）：161.
[4]	张齐，赵成军，王燕.前列地尔联合高压氧治疗肝硬化合肝肺综合征的临床研究[J].临床医药文献杂志，2017，4（64）：12609-12610.
[5]	中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防冶指南（2010年版）[J].中华肝脏病杂志，2011，19（1）：13-14.
[6]	高咏梅，刘云峰，姚金锋，等.前列地尔治疗肝硬化并肝肾综合征的疗效观察[J].河北医药，2015，37（4）：551-553.
[7]	郝爱芹.恩替卡韦与前列地尔联合治疗乙型肝炎肝硬化腹水的效果及对患者肝功能的影响[J].河南医学研究，2017，26（5）：838-839.
[8]	龙志玲，邵泽勇，伍锡刚，等.前列地尔联合复方鳖甲软肝片治疗慢性乙型肝炎肝硬化的疗效观察[J].现代药物与临床，2018，33（1）：134-138.
[9]	刘德孔，沈家豪，凌月成.奥曲肽联合前列地尔治疗肝硬化合并肝肾综合征疗效及对患者肝肾功能影响[J].浙江中西医结合杂志，2017，27（6）：487-489.
[10]	鲁慧东.失代偿期乙型肝炎肝硬化治疗中替比夫定的应用效果及安全性分析[J].中国实用医药，2017，12（15）：92-93.
[11]	鲁慧东.肝硬化难治性腹水患者行特利加压素搭配前列地尔治疗的疗效[J].中国实用医药，2017，12（18）：103-105.
[12]	宋木生.慢性乙型肝炎肝硬化应用替比夫定联合前列地尔治疗的临床效果[J].数理医药学杂志，2015，28（10）：1521-1522.
[13]	占红，张红霞.前列地尔治疗肝硬化难治性腹水的近远期疗效观察[J].中国中西医结合消化杂志，2017，25（3）：199-205.
[14]	陈逊，刘海滨.前列地尔联合替比夫定对乙肝肝硬化患者疗效和血清炎性因子的影响[J].河北医学，2017，23（12）：1963-1966.
[15]	王忠琼，刘翼，夏国栋，等.前列地尔对乙肝肝硬化患者血清炎性因子及肝功能的影响[J].医学研究生学报，2017，30（6）：611-614.